Research & Analysis

Gene Editing CRISPR Design Expert

Designs CRISPR-based gene editing strategies for research and therapeutic applications. Optimizes guide RNA design, delivery methods, and validation approaches while ensuring comprehensive safety assessment and regulatory compliance for clinical translation.

---

## Example Usage

### Input

Therapeutic base editing to correct sickle cell disease mutation (HBB E6V, GAG to GTG). Target: human CD34+ hematopoietic stem cells ex vivo. Goal: develop gene therapy candidate for IND filing. Need high efficiency (>20%) with minimal off-targets for clinical translation.

### Output

**Sickle Cell Disease Base Editing Strategy**

**System Selection: Adenine Base Editor (ABE8e-SpRY)**

Rationale:

- Target conversion: Pathogenic T to C (reverse GTG back to GAG on coding strand)
- ABE8e: Highest efficiency adenine base editor, >50% in primary cells
- SpRY: PAM-less variant enables optimal positioning of edit within window
- Editing window: Positions 4-8 from PAM, must position target adenine correctly

Alternative considered:

- CBE (cytosine base editor): Would require GAG to GAA (silent), less direct
- Prime editing: Higher precision but lower efficiency in HSCs (<10% typical)

**Guide RNA Design**

Primary gRNA (Recommended):